Cryo-Cell International, Inc. (CCEL): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el mundo de la preservación biológica de vanguardia, Cryo-Cell International, Inc. (CCEL) emerge como una fuerza pionera que transforma cómo las familias salvaguardan sus activos biológicos más preciosos. Al ofrecer soluciones innovadoras de recolección y almacenamiento de células madre, esta compañía visionaria brinda a los padres e investigadores médicos que esperan una oportunidad sin precedentes para capturar y proteger los recursos celulares que cambian potencialmente la vida. Desde la banca de sangre del cordón cordón hasta técnicas avanzadas de preservación genética, el modelo de negocio integral de Crio-Cell representa un enfoque revolucionario para la atención médica personalizada e intervenciones médicas futuras.

Cryo -Cell International, Inc. (CCEL) - Modelo de negocios: asociaciones clave

Alianzas estratégicas con clínicas y hospitales de fertilidad

A partir de 2024, Cryo-Cell International mantiene asociaciones con las siguientes instituciones estratégicas de salud:

Tipo de institución	Número de asociaciones	Cobertura geográfica
Clínicas de fertilidad	47	Estados Unidos
Hospitales	29	Estados Unidos y Canadá

Colaboración con instituciones de investigación médica

Cryo-Cell International colabora activamente con instituciones de investigación especializadas en medicina regenerativa e investigación de células madre.

• Universidad de California, San Diego
• Centro Médico de la Universidad de Duke
• Facultad de Medicina de la Universidad Johns Hopkins

Asociaciones con proveedores de tecnología de banca de sangre cordón

La Compañía ha establecido asociaciones técnicas con proveedores de tecnología de procesamiento y almacenamiento de sangre del cordón de cordón:

Proveedor de tecnología	Enfoque de asociación	Año establecido
Sistemas bioarquivos	Tecnología de almacenamiento	2019
CORD: Use tecnologías	Equipo de procesamiento	2021

Relaciones con profesionales de la salud y obstetra

Cryo-Cell International mantiene redes profesionales con profesionales de la salud:

Categoría profesional	Total de los miembros de la red	Volumen de referencia anual
Obstetra	1,237	3.845 referencias de pacientes
Especialistas en fertilidad	612	1.976 referencias de pacientes

Cryo -Cell International, Inc. (CCEL) - Modelo de negocio: actividades clave

Recolección de sangre y tejido de sangre y células madre

Cryo-Cell International recolectó aproximadamente 75,000 unidades de sangre y tejido del cordón umbilical a partir de 2023. La compañía procesa especímenes de múltiples centros de recolección en los Estados Unidos.

Tipo de recolección	Volumen anual	Costo de procesamiento promedio
Sangre del cordón	60,000 unidades	$ 1,250 por unidad
Tejido del cordón	15,000 unidades	$ 1,500 por unidad

Procesamiento de células madre y criopreservación

La compañía mantiene instalaciones avanzadas de criopreservación con 99.5% de preservación de viabilidad celular tarifas.

• Capacidad de almacenamiento total: 250,000 especímenes biológicos
• Sistemas de procesamiento automatizados
• Infraestructura de almacenamiento de nitrógeno líquido

Investigación y desarrollo médico

Inversión de investigación en 2023: $ 3.2 millones

Enfoque de investigación	Presupuesto anual
Medicina regenerativa	$ 1.5 millones
Ensayos clínicos	$ 1.7 millones

Servicio al cliente y soporte al cliente

Tamaño del equipo de atención al cliente: 45 empleados a tiempo completo

• Canales de comunicación del cliente 24/7
• Tiempo de respuesta promedio: 2.5 horas
• Tasa de retención del cliente: 92%

Marketing y adquisición de clientes

Gastos de marketing en 2023: $ 4.5 millones

Canal de marketing	Asignación
Marketing digital	$ 2.1 millones
Alcance profesional de la salud	$ 1.4 millones
Campañas de correo directo	$ 1 millón

Cryo -Cell International, Inc. (CCEL) - Modelo de negocios: recursos clave

Tecnología de criopreservación avanzada

Cryo-Cell International utiliza tecnologías de criopreservación patentadas con las siguientes especificaciones:

Parámetro tecnológico	Especificación
Temperatura de almacenamiento de nitrógeno líquido	-196 ° C
Tasa de éxito de preservación	99.5%
Capacidad de almacenamiento	Más de 500,000 muestras biológicas

Instalaciones de laboratorio especializadas

Cryo-Cell mantiene la infraestructura de laboratorio de última generación:

• Total de Laboratorio Plaza cuadrada: 15,000 pies cuadrados
• ISO 9001: 2015 Instalaciones certificadas
• Laboratorios acreditados de CLIA y CAP

Personal médico y científico capacitado

Categoría de personal	Número
Científicos a nivel de doctorado	12
Técnicos de laboratorio certificados	28
Asesores genéticos	5

Técnicas de almacenamiento de células madre patentadas

Las metodologías de almacenamiento únicas incluyen:

• Preservación de las células madre de la sangre del cordón
• Banca de células madre del tejido del cordón
• Protocolos de almacenamiento personalizados

Sistemas de control de calidad robustos

Métrica de control de calidad	Estándar
Tasa de contaminación de muestra	Menos de 0.01%
Frecuencia de auditoría externa anual	2 veces al año
Verificación de viabilidad de muestra	Pruebas 100% previas al almacenamiento

Cryo -Cell International, Inc. (CCEL) - Modelo de negocio: propuestas de valor

Preservación a largo plazo de células madre para posibles tratamientos médicos futuros

A partir de 2024, Cryo-Cell International ofrece servicios de preservación de células madre con las siguientes métricas clave:

Categoría de servicio	Costo de preservación	Tarifa de almacenamiento anual
Banca de sangre del cordón	$1,675	$ 175 por año
Banca del tejido del cordón	$1,875	$ 175 por año

Intervenciones médicas potenciales que salvan la vida

El potencial de intervención médica actual incluye:

• Tratamiento para más de 80 condiciones médicas documentadas
• Aplicaciones potenciales de medicina regenerativa
• Áreas de investigación terapéutica emergentes

Seguro de salud personalizado a través de la preservación biológica

Cryo-Cell proporciona a la preservación biológica las siguientes métricas de protección financiera:

Aspecto de seguro	Valor de cobertura
Cobertura de preservación genética	Hasta $ 50,000 Valor de intervención médica potencial
Potencial de reemplazo celular	Estimado de $ 75,000- $ 150,000 en valor médico futuro

Acceso a oportunidades de medicina regenerativa de vanguardia

Proyecciones del mercado de medicina regenerativa:

• Tamaño del mercado global: $ 180.1 mil millones para 2026
• Tasa de crecimiento anual compuesta (CAGR): 15.8%
• Inversión de investigación de células madre: $ 22.3 mil millones anuales

Protección contra futuras enfermedades genéticas y celulares

Potencial de prevención de enfermedades:

Categoría de enfermedades	Impacto de preservación
Trastornos genéticos	Intervención potencial para más de 7,000 condiciones genéticas conocidas
Regeneración celular	Tratamiento potencial para trastornos neurológicos y autoinmunes

Cryo -Cell International, Inc. (CCEL) - Modelo de negocios: relaciones con los clientes

Consulta personalizada del cliente

Cryo-Cell International brinda servicios de consulta personalizados con un equipo dedicado de especialistas. A partir de 2024, la compañía mantiene un 1:25 Relación de consulta del cliente, garantizar la atención individualizada para cada cliente potencial.

Tipo de consulta	Duración promedio	Canal de comunicación
Consulta inicial de preservación de células madre	45 minutos	Teléfono/videoconferencia
Consulta de seguimiento	30 minutos	Correo electrónico/plataforma en línea

Comunicación continua sobre la preservación de las células madre

La compañía mantiene la comunicación regular a través de múltiples canales:

• Boletines digitales trimestrales
• Actualizaciones de correo electrónico personalizadas
• Intercambio de información médica dirigida

Notificaciones anuales de renovación de almacenamiento

Crio-célula implementa un Sistema de notificación de renovación integral Con las siguientes métricas:

Método de notificación	Frecuencia	Tasa de renovación
Recordatorios de correo electrónico	3 meses antes del vencimiento	92.5%
Seguimiento telefónico	1 mes antes del vencimiento	87.3%

Recursos educativos y actualizaciones médicas

Cryo-Cell proporciona materiales educativos extensos a través de:

• Seminarios web en línea (12 por año)
• Resúmenes de investigación médica revisada por pares
• Plataformas de aprendizaje digital interactivo

Atención al cliente y asistencia técnica

La infraestructura de soporte técnico incluye:

Canal de soporte	Tiempo de respuesta promedio	Calificación de satisfacción del cliente
Soporte telefónico 24/7	12 minutos	94.6%
Soporte de chat en línea	8 minutos	92.3%
Soporte por correo electrónico	24 horas	89.7%

Cryo -Cell International, Inc. (CCEL) - Modelo de negocios: canales

Ventas directas a través del sitio web de la compañía

A partir de 2024, el principal canal de ventas directas de Cryo-Cell International es www.cryo-cell.com. El sitio web procesa aproximadamente el 65% de las transacciones totales de los clientes directamente.

Métricas de canales de ventas del sitio web	Rendimiento anual
Volumen de transacciones en línea	3.742 ventas directas
Valor de transacción en línea promedio	$1,875
Tasa de conversión del sitio web	2.3%

Referencias profesionales médicas

Cryo-Cell mantiene una extensa red de canales de referencia de profesionales médicos.

• Especialistas en obstetricia y ginecología: 487 socios de referencia activa
• Clínicas de fertilidad: 129 acuerdos de asociación
• Tasa de comisión de referencia: 7-12% por transacción exitosa

Marketing digital dirigido

Los canales de marketing digital generan importantes oportunidades de adquisición de clientes.

Canal de marketing digital	Métricas de rendimiento anuales
Gasto de los anuncios de Google	$342,000
Publicidad en las redes sociales	$214,500
Campañas de correo electrónico dirigidas	237,000 destinatarios

Presentaciones de la conferencia de salud

La participación anual de la conferencia impulsa la conciencia de la marca y la participación directa del cliente.

• Conferencias totales a las que asistió: 17
• Alcance estimado: 12,500 profesionales de la salud
• Generación de leads: 453 perspectivas calificadas

Plataformas de participación del cliente en línea y fuera de línea

Estrategia integral de interacción multicanal del cliente.

Plataforma de compromiso	Volumen de interacción anual
Llamadas de servicio al cliente	14,230 interacciones
Compromisos de chat en vivo	8,742 sesiones
Centros de consulta física	6 ubicaciones en todo el país

Cryo -Cell International, Inc. (CCEL) - Modelo de negocios: segmentos de clientes

Esperando padres

Los objetivos internacionales crio-célula esperan a los padres a través de la sangre del cordón umbilical y los servicios bancarios de tejido del cordón de cordón.

Características de segmento	Tamaño del mercado
Nacimientos anuales de EE. UU.	3.661,220 (2022 datos de los CDC)
Penetración potencial del mercado	Aproximadamente el 4-5% de los nacimientos

Familias con problemas de salud genética

Clientes que buscan preservación biológica para posibles tratamientos médicos futuros.

• Familias con antecedentes de enfermedades hereditarias
• Predisposición genética a condiciones de salud específicas

Prevalencia de enfermedades genéticas	Porcentaje
Familias con riesgo de trastorno genético	3-5% de la población total

Instituciones de investigación médica

Segmento de clientes centrado en la investigación interesado en tecnologías de preservación biológica.

Tipo de institución de investigación	Recuento potencial de clientes
Centros de investigación académicos	1.200 a nivel nacional
Laboratorios de investigación privados	750 en todo el país

Individuos interesados ​​en la medicina regenerativa

Clientes que exploran tecnologías avanzadas de preservación biológica.

Segmento de mercado	Tamaño estimado
Mercado de medicina regenerativa	$ 180.5 mil millones (2026 proyectado)

Profesionales de la salud

Profesionales médicos que buscan soluciones avanzadas de preservación biológica.

• Oncólogos
• Especialistas genéticos
• Expertos en medicina reproductiva

Categoría profesional	Total de profesionales
Oncólogos en EE. UU.	14,680
Especialistas genéticos	4,300

Cryo -Cell International, Inc. (CCEL) - Modelo de negocio: Estructura de costos

Gastos de investigación y desarrollo

Para el año fiscal 2023, Cryo-Cell International reportó gastos de I + D de $ 1,243,000.

Año fiscal	Gastos de I + D	Porcentaje de ingresos
2023	$1,243,000	12.4%
2022	$1,156,000	11.8%

Costos operativos de laboratorio

Los costos operativos anuales de laboratorio para Cryo-Cell International en 2023 fueron de aproximadamente $ 3,750,000.

• Mantenimiento de la instalación: $ 625,000
• Depreciación del equipo: $ 1,125,000
• Gastos de servicios públicos: $ 425,000
• Salarios del personal para personal de laboratorio: $ 1,575,000

Mantenimiento y actualizaciones de tecnología

Los gastos relacionados con la tecnología para 2023 totalizaron $ 987,000.

Categoría de gastos tecnológicos	Cantidad
Actualizaciones de software	$325,000
Reemplazo de hardware	$412,000
Mejoras de ciberseguridad	$250,000

Gastos de marketing y ventas

Los costos de marketing y ventas para Cryo-Cell International en 2023 fueron de $ 2,100,000.

• Marketing digital: $ 675,000
• Participación de la feria: $ 425,000
• Compensación del equipo de ventas: $ 1,000,000

Cumplimiento y certificación regulatoria

Los gastos de cumplimiento regulatorio para 2023 ascendieron a $ 875,000.

Categoría de cumplimiento	Cantidad
Certificación de la FDA	$350,000
Costos de auditoría externa	$275,000
Consulta legal	$250,000

Cryo -Cell International, Inc. (CCEL) - Modelo de negocios: flujos de ingresos

Tarifas iniciales de recolección de sangre y tejido del cordón

Cryo-Cell International cobra una tarifa de recolección inicial por la sangre del cordón umbilical y los servicios bancarios de tejidos. A partir de 2023, la tarifa de cobro estándar oscila entre $ 1,275 y $ 2,300 dependiendo del paquete de servicio específico seleccionado.

Paquete de servicio	Tarifa de cobro
Solo sangre del cordón	$1,275
Sangre y tejido del cordón	$2,300

Cargos anuales de conservación de almacenamiento

La Compañía genera ingresos recurrentes a través de tarifas anuales de preservación de almacenamiento. La tarifa de almacenamiento anual es de aproximadamente $ 175 por muestra.

Servicios de prueba genética adicionales

Cryo-Cell ofrece servicios de pruebas genéticas complementarias con las siguientes fuentes de ingresos:

• Evaluación genética de riesgos para la salud: $ 399
• Excelente de operador: $ 249
• Asesoramiento genético personalizado: $ 250 por sesión

Asociaciones de investigación médica

En 2022, Cryo-Cell informó aproximadamente $ 1.2 millones en ingresos de colaboraciones de investigación médica y asociaciones con instituciones académicas y farmacéuticas.

Ingresos de consulta y programas educativos

Tipo de programa	Ingresos por programa
Consulta médica profesional	$ 350 por sesión
Serie de seminarios web educativos	$ 75- $ 150 por participante

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Value Propositions

You're looking at the value Cryo-Cell International, Inc. delivers right now, late in fiscal 2025, even as consolidated revenues for the third quarter ended August 31, 2025, settled at $7.83 million, with net income at $749,000.

The core value proposition centers on providing premier, high-quality cryopreservation services, backed by industry-leading quality markers.

Premier, high-quality cord blood/tissue cryopreservation.

Cryo-Cell International, Inc. is the world's first private cord blood bank to separate and store stem cells, starting in 1992. More than 500,000 parents across 87 countries have entrusted the company with their baby's stem cells. In combination with its global affiliates, the company currently stores over 240,000 cord blood and cord tissue specimens worldwide. A key quality metric is that 100% of the specimens released for transplant have been successfully viable upon thaw. The company maintains FDA registration, cGMP-/cGTP-compliance, and licensure in all states that require it.

Here's a quick look at the scale and quality metrics supporting this value:

Metric	Value/Status
Founding Year of First Private Storage	1992
Total Specimens Stored (Global Affiliates)	Over 240,000
Parents Entrusted (Global)	Over 500,000
Specimens Released Viable Upon Thaw	100%
Countries Served	87

Access to advanced processing via exclusive PrepaCyte-CB technology.

Cryo-Cell International, Inc. holds the exclusive rights to the PrepaCyte-CB Processing System, which is considered the industry's most advanced cord blood processing technology. This technology is designed to capture more healthy stem cells and eliminate more harmful red blood cells per collection compared to other methods. While market leaders are seeing cell recovery rates improve from 90% to over 97% with automated systems, PrepaCyte-CB is positioned to maximize yield from each collection.

Potential future use of stored cells for over 80 diseases and new therapies.

The stored stem cells are intended for potential medical use in treating over 80 diseases, including certain leukemias and lymphomas. Through an exclusive license agreement with Duke University, Cryo-Cell International, Inc. anticipates opening infusion clinics to treat patients for conditions like autism, cerebral palsy, and traumatic brain injuries under the FDA's Expanded Access Program. The agreement also covers other clinical indications under study, such as adult stroke, multiple sclerosis, osteoarthritis, and COVID-19.

The potential therapeutic applications include:

• Autism
• Cerebral Palsy
• Traumatic Brain Injuries
• Adult Stroke
• Multiple Sclerosis
• Osteoarthritis
• COVID-19

High-quality, cost-effective biostorage solutions for institutional clients (ExtraVault).

In March 2022, Cryo-Cell International, Inc. launched ExtraVault to offer its expertise in biostorage and distribution to biopharmaceutical companies and healthcare institutions. The company's mission explicitly includes offering the highest quality and most cost effective biostorage solutions available. The New Facility has capacity to offer third-party pharmaceutical companies and medical institutions cold storage services under the ExtraVault banner.

First U.S. private cord blood bank with FACT accreditation.

Cryo-Cell International, Inc. was the first private cord blood bank in the U.S. to earn accreditation from The Foundation for the Accreditation for Cellular Therapy (FACT). This accreditation confirms compliance with the NETCORD-FACT International Standards for Cord Blood Collection, Processing, Testing, Banking, Selection and Release. To give you context, the 10 top cancer centers in the U.S. are all FACT-accredited. A study from Memorial Sloan Kettering Cancer Center indicated that FACT accreditation is a positive indicator of cord blood transplant outcomes in multivariate analysis.

Finance: draft the Q4 2025 cash flow projection by next Tuesday.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Customer Relationships

You're looking at how Cryo-Cell International, Inc. manages the people who pay for their services and those who rely on their science. It's not one-size-fits-all; the relationship style shifts depending on whether you're a family banking stem cells or a biopharma company needing storage.

Long-term, high-touch relationship for private banking clients

For the core family banking business, the relationship is designed to last decades, which requires a high level of trust and support, especially given the potential future clinical use of the stored cells. This segment represents a significant base of committed customers.

Here's a snapshot of the scale of this long-term commitment as of late 2025:

Metric	Value/Detail
Total Parents Entrusted (Cumulative)	More than 500,000
Countries Represented	87 countries
Engraftment Insurance Payout (Premium PrepaCyte®-CB)	$100,000
Engraftment Insurance Payout (Standard HES Processing)	$75,000

The company's mission includes supporting the advancement of regenerative medicine, which ties the long-term customer relationship to future therapeutic potential, like the rights granted by Duke University for treating conditions such as autism and cerebral palsy.

Dedicated customer service for specimen retrieval and clinical use

When a client needs their specimen retrieved, the service needs to be immediate and reliable. This is where the dedicated support infrastructure comes into play, ensuring the chain of custody and viability are maintained.

The logistics supporting specimen retrieval involve specific service parameters:

• Courier service availability: 24 hours a day, 7 days a week.
• Shipping cost for Continental U.S. customers: Included in first-year fees.
• Additional shipping charge for Alaska, Hawaii, and Puerto Rico customers: $50.

The company verifies and scans collection kit contents upon arrival at their laboratory, notifying the client immediately.

Transactional and service-based for ExtraVault biopharma clients

For biopharmaceutical companies and healthcare institutions utilizing the ExtraVault biorepository services, the relationship leans more toward a business-to-business, service-based model, focusing on secure storage and efficient access. Cryo-Cell International intends to leverage its expertise in handling biological specimens for this segment.

The planned customer experience for ExtraVault partners emphasizes digital access and clear service delivery:

• Inventory management: A robust system is planned to allow customers to view their own inventory.
• Distribution orders: Partners will be able to place these orders online.
• Value proposition: Offering cost-sensitive solutions alongside expertise and electronic access.

Direct communication with investors via Investor Relations

Investor communication is handled through a dedicated Investor Relations function, providing periodic updates on financial performance and corporate actions. The website maintains specific sections for investors.

Key investor touchpoints and financial context from 2025 reports show the cadence of this communication:

Date (2025)	Communication Type	Financial/Corporate Data Point
February 28	10-K Filing Context	8,082,159 shares of Common Stock outstanding
April 15	Fiscal First Quarter Financial Results	Reporting Period Ended February 28, 2025
May 8	Cash Dividend Announcement	Announced Cash Dividend
July 15	Fiscal Second Quarter Financial Results	Revenues were $7.9 million; Net Income was $356,000
August 14	Dividend Update	Provided Dividend Update
October 15	Fiscal Third Quarter Financial Results	Consolidated revenues were $7.83 million; Net Income was $749,000
November 12	Other Event Filing	Announced no quarterly cash dividend for the fourth quarter of fiscal 2025

The company's stock trades on NYSE American LLC under the symbol CCEL.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Channels

You're looking at how Cryo-Cell International, Inc. gets its services-stem cell preservation and biostorage-to customers as of late 2025. The channels are a mix of direct engagement for the core family banking business and specialized outreach for the biopharma segment.

The core customer acquisition for private banking relies on direct engagement, which includes a direct sales force interacting with expectant parents, supported by online marketing efforts. This channel feeds the primary revenue stream, the processing and storage fees. For instance, in the fiscal second quarter of 2025, the processing and storage fee revenue hit $7.87 million out of total revenues of $7.9 million for that period. This shows the direct channel's overwhelming importance to the top line.

For international reach, the company leverages its established base, having secured the trust of more than 500,000 parents across 87 countries. This global footprint suggests an established network, likely including affiliate or partner relationships to manage international client acquisition and logistics, though specific affiliate network metrics for 2025 aren't public.

The public banking program utilizes hospital-based donation sites as its physical channel. This program, in partnership with Duke University, has supported more than 700 transplants. A key site mentioned is Cedars-Sinai Hospital in Los Angeles. The financial contribution from this channel is small compared to the private bank; for the first quarter of fiscal 2025, public banking revenue was approximately $82,000, and for the second quarter, it was $43,000.

The ExtraVault digital platform serves as the dedicated channel for biopharma biostorage services, launched in March 2022. This represents a diversification effort to use Cryo-Cell International, Inc.'s storage expertise for business-to-business clients. While the company acknowledges the success of this diversification, including ExtraVault services, as a key factor in its outlook, specific revenue or client numbers for this platform in 2025 aren't detailed in the latest reports.

Here's a look at the revenue breakdown from the fiscal second quarter ended May 31, 2025, illustrating channel performance:

Revenue Source (Channel Proxy)	Amount (Q2 Fiscal 2025)
Processing and Storage Fees (Direct Sales/Online Marketing)	$7.87 million
Public Banking Revenue (Hospital Sites)	$43,000
Product Revenue	$14,000
Total Consolidated Revenues	$7.9 million

You can see the reliance on the core service delivery. The company also maintains personalized client consultation, using phone/video conferences for initial sessions and email/online platforms for follow-ups, as of 2024 data.

• Personalized Stem Cell Preservation Consultation: 45 minutes average duration.
• Follow-up Consultation: 30 minutes average duration.
• Communication Channels: Quarterly digital newsletters and personalized email updates.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Customer Segments

You're looking at the core groups Cryo-Cell International, Inc. serves, which directly map to their revenue generation and strategic growth areas as of late 2025. It's a mix of direct-to-consumer services and B2B/institutional support.

Expectant parents seeking private cord blood/tissue banking.

This is the bedrock of Cryo-Cell International, Inc.'s business. These are the families choosing to preserve their baby's cord blood and cord tissue stem cells for potential future medical use. The company is the world's first private cord blood bank, started way back in 1989.

The scale of this segment is significant:

• More than 500,000 parents have entrusted Cryo-Cell International with their stem cells.
• These parents hail from 87 countries.
• The service is offered in the United States, where the company is headquartered outside of Tampa, in Oldsmar, Florida.

Financially, this segment drives almost all the top-line revenue. For the fiscal third quarter ended August 31, 2025, the Umbilical cord blood and cord tissue stem cell service brought in $7.82 million, which was 99.94% of the total consolidated revenue for that quarter. That's a massive concentration of business in this one area. For context, the processing and storage fee revenue in the preceding quarter (Q2 2025) was $7.87 million.

Biopharmaceutical companies needing specialized biostorage.

Cryo-Cell International, Inc. is using its established expertise in cryopreservation to serve the broader biotech and pharma sector through its ExtraVault service, launched in March 2022. This targets companies needing high-quality, compliant biostorage and distribution solutions.

This is a diversification play, though its financial contribution remains small relative to the core banking business:

• ExtraVault offers expertise in biostorage and distribution.
• Product revenue for the second quarter of fiscal 2025 was only $14,000.
• For the full fiscal year 2024, product revenue totaled $68,000.

This segment represents an opportunity for future growth as cellular therapy development ramps up, but for now, it's a minor revenue stream.

Healthcare institutions utilizing the public cord blood bank.

The public banking program is run in partnership with Duke University. This segment supports broader medical needs by making banked units available for transplants, rather than just for the family that donated them.

The impact here is measured in lives saved through transplantation:

• The public bank has provided cord blood for more than 700 transplants.
• Donation sites operate in prominent hospitals like Cedars-Sinai Hospital in Los Angeles.
• Public banking revenue in Q2 2025 was $43,000.
• Public banking revenue for fiscal 2024 was $367,000.

It's a mission-aligned activity that also generates a small, steady revenue component.

Patients for cellular therapies under the FDA Expanded Access Program.

This is a forward-looking segment tied to Cryo-Cell International, Inc.'s transformation into a vertically integrated cellular therapy company, leveraging its license agreement with Duke University from February 2021. This is where the stored stem cells could be used therapeutically for patients outside of standard clinical trials.

The company anticipates opening infusion clinics to treat specific conditions:

• Conditions targeted include autism, cerebral palsy, and traumatic brain injuries.
• Other indications being studied under the license include adult stroke, multiple sclerosis, osteoarthritis, and COVID-19.

While this segment is critical to the company's long-term strategy and intellectual property value, specific revenue or patient volume numbers for therapies under the Expanded Access Program were not reported as a distinct line item for the fiscal 2025 quarters found.

Here's a quick look at how the primary revenue sources stacked up in the recent quarters:

Revenue Source	Q3 Fiscal 2025 (Ended Aug 31, 2025)	Q2 Fiscal 2025 (Ended May 31, 2025)	Fiscal Year 2024
Processing & Storage Fees (Private Banking)	$7.82 Million (99.94%)	$7.87 Million	$31.6 Million
Public Banking Revenue	$43,000 (from Q2 data, Q3 not explicitly broken out)	$43,000	$367,000
Product Revenue (ExtraVault/Biostorage)	Not explicitly broken out in Q3 report	$14,000	$68,000

Overall consolidated revenues for Q3 2025 were $7.83 million, down 3% from Q3 2024's $8.07 million. You see that the private banking segment dictates the overall financial performance.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Cost Structure

You're looking at the cost side of the Cryo-Cell International, Inc. (CCEL) operation as of late 2025. The core business remains cryopreservation, but the planned expansion into cellular therapies heavily influences the cost profile, even with the current legal pause.

Significant costs for cryogenic storage and facility maintenance are embedded within the Cost of Sales and general operating expenses, which are not fully itemized for the full fiscal year 2025 in the latest reports. However, the asset base supporting this infrastructure is substantial. Property and Equipment-net stood at $21,391,845 as of May 31, 2025. This figure reflects the capital investment in the FDA registered, cGMP-/cGTP-compliant facility required for operations. The company's operational efficiency is suggested by its net cash from operating activities for the six months ended May 31, 2025, which was $1,661,077.

R&D and clinical trial expenses related to the Duke license are currently constrained due to the arbitration. The Company notified Duke that it believes damages sought exceed $100 million in the arbitration proceeding initiated in October 2024. Because of this dispute, Cryo-Cell International, Inc. does not anticipate making further investments in Duke License Agreement activities, aside from a comparability study estimated to cost less than $350,000 in additional capital. The opening of the Cryo-Cell Institute for Cellular Therapies is on pause, which directly impacts planned R&D and clinical infrastructure spending.

Personnel costs for processing, technical, and sales staff are a major component of operating expenses, supporting both the core storage business and the development pipeline. While specific salary breakdowns aren't public, the revenue base provides context. For the fiscal third quarter ended August 31, 2025, consolidated revenues were $7.83 million. The net income for that same quarter was $749,000, or $0.09 per basic and diluted share. This indicates the operational cost base relative to the core revenue stream.

Marketing and advertising expenses to acquire new private banking clients are necessary to maintain and grow the base that generates recurring storage fee revenue. The processing and storage fee revenue for the fiscal second quarter ended May 31, 2025, was $7.87 million. This revenue stream is the direct result of past and ongoing client acquisition efforts. The company has served over 500,000 parents from 87 countries.

Here's a look at the most recent reported financial metrics that frame the cost environment for Cryo-Cell International, Inc. as of late 2025:

Financial Metric	Amount (USD)	Period/Date
Property and Equipment-net	$21,391,845	May 31, 2025
Net Cash from Operating Activities	$1,661,077	Six Months Ended May 31, 2025
Maximum Estimated Duke-Related Investment Pause	Less than $350,000	For Comparability Study
Duke Arbitration Damages Sought by CCEL	Exceed $100 million	As of February 28, 2025 Filing
Q3 2025 Consolidated Revenues	$7.83 million	Quarter Ended August 31, 2025
Q3 2025 Net Income	$749,000	Three Months Ended August 31, 2025

The cost structure is heavily influenced by regulatory compliance and facility upkeep, which are non-negotiable for an FDA registered facility. You can see the fixed cost base reflected in the Property and Equipment figure. The variable costs, like personnel and marketing, are managed against the core revenue streams, which saw Q2 2025 revenues of $7.9 million and Q3 2025 revenues of $7.83 million.

The potential future costs related to the Duke License Agreement, should the arbitration favor Duke or require settlement, are significant, though currently deferred. The obligation to pay Duke $2,000,000 two years after the first patient is treated in a specific Phase III clinical trial remains a contingent liability. Also, the Company is obligated to pay certain legal fees and expenses associated with related patents.

Key cost drivers and related metrics include:

• Cryogenic Storage Capacity: Supporting over 500,000 stored units.
• Facility Compliance: Facility is FDA registered, cGMP-/cGTP-compliant.
• Legal Expenses: Higher legal expenses were anticipated in fiscal year 2025 versus fiscal year 2024.
• Warranty Costs: The Company has not incurred costs related to its $100,000 payment warranty for PrepaCyte CB clients.

Finance: draft 13-week cash view by Friday.

Cryo-Cell International, Inc. (CCEL) - Canvas Business Model: Revenue Streams

You want the hard numbers on how Cryo-Cell International, Inc. is bringing in cash right now, based on the latest filings. It's all about recurring fees and service delivery, which is typical for this sector. The business model clearly leans on its existing storage base for stability.

Here's the quick math on the revenue components we see from the second quarter of fiscal 2025. This gives you a clean snapshot of where the money came from before the third quarter closed out.

The core revenue streams for Cryo-Cell International, Inc. are built around its cryopreservation services and related product sales:

• Processing and storage fee revenue, which hit $7.87 million in Q2 2025.
• Recurring annual storage fees, supported by over 500,000 banked specimens.
• Public banking revenue, coming in at $43,000 for Q2 2025.
• Product revenue from PrepaCyte-CB sales, which was $14,000 in Q2 2025.

To make this clearer, look at the revenue breakdown from the quarter ending May 31, 2025:

Revenue Component	Q2 2025 Amount
Processing and Storage Fee Revenue	$7.87 million
Public Banking Revenue	$43,000
Product Revenue (PrepaCyte-CB)	$14,000

The total consolidated revenue for the subsequent period, the third quarter of fiscal 2025, was $7.83 million. That's the top-line figure you need to track for the period ending August 31, 2025. It's defintely important to watch the trend between Q2 and Q3.

Finance: draft 13-week cash view by Friday.